Circadin is commonly used to help with specific sleep-related symptoms that interfere with daily functioning. The main therapeutic area contributes to easing the overall symptom load in conditions characterized by periods of heightened symptoms, specifically those relating to poor quality of sleep.

The medication is applied in clinical settings that involve acute or unstable symptom patterns. It is relevant for managing symptoms related to systemic imbalance commonly linked to difficulties in initiating or maintaining sleep. The medication may assist with managing symptoms that become more disruptive during flare-ups, and is applied in addressing symptoms associated with acute or episodic changes.

“It supports the patient during difficult episodes by easing distress and is relevant for easing symptoms related to heightened physiological activity.”

The application is considered relevant in specific patient populations, where symptoms may intensify temporarily. It helps maintain a sense of stability when symptoms are more noticeable, and provides supportive relief when symptoms that interfere with daily functioning are present.

Quick Fact: Relief for symptoms related to physical discomfort associated with primary insomnia.

Regulatory References

1. European Medicines Agency (EMA) Summary of Product Characteristics

Who Can and Cannot Use Circadin?

The population eligibility for Circadin (melatonin prolonged-release) is strictly defined by regulatory documents, limiting use to specific groups.

---

Official Eligibility Constraints

Classification	Population/Condition
Indicated Use	Patients aged 55 years and over for short-term treatment of primary insomnia.
Absolute Contraindication	Known hypersensitivity to melatonin or excipients; certain rare hereditary sugar intolerances.
Not Recommended Use	Children and adolescents (under 18 years); patients with hepatic impairment (liver problems); patients with autoimmune diseases.
Pregnancy/Lactation	Not recommended for use in women who are pregnant or breastfeeding.

---

Regulatory Basis for Use

Circadin's use is officially not recommended in several key populations, including the pediatric group, as safety and efficacy have not been established. Use requires caution in patients with severe renal impairment. These constraints ensure the medicine is limited to the demographic where its effects have been officially documented and reviewed.

Interactions with other medicines and products

Circadin's interaction profile is defined by its metabolic clearance and the potential for additive effects with other central nervous system (CNS) agents. Co-administration with fluvoxamine should be avoided due to its documented ability to significantly inhibit melatonin clearance, resulting in greatly increased plasma exposure.

Several other medicinal products are known to influence Circadin's levels. Substances that inhibit the responsible enzymes (CYP1A2 and others), such as oestrogens, cimetidine, and quinolones, may also lead to increased melatonin plasma concentrations. Conversely, enzyme inducers like carbamazepine, rifampicin, and cigarette smoking are documented to reduce the drug's plasma levels.

A separate interaction type involves pharmacodynamic reinforcement. Co-administration with benzodiazepines (including zolpidem) and certain antipsychotics (thioridazine) or antidepressants (imipramine) may enhance sedative properties and increase impairment of attention or coordination.

Specific restrictions apply to other substances: alcohol consumption is documented to reduce Circadin's effectiveness on sleep, and the medication must be administered after food to maintain its prolonged-release characteristics. Furthermore, Circadin is not recommended for use in patients with hepatic impairment due to decreased drug clearance.

The active ingredient in Circadin, a synthetic analog of the naturally occurring hormone, acts on melatonin receptors in the central nervous system. Specifically, the substance functions as a full agonist at the MT1 and MT2 receptors located in the suprachiasmatic nucleus (SCN) of the hypothalamus.

Agonism at the MT1 receptor is associated with the promotion of sleep onset. Agonism at the MT2 receptor mediates the phase-shifting of the circadian rhythm. Through interaction with these receptors, the active substance modulates the timing and phase of the circadian rhythm.

The prolonged-release formulation ensures a sustained systemic concentration over a period of 8–10 hours. This sustained action contributes to the modulation of arousal-related neurotransmitter release and the subsequent signaling pathways responsible for coordinating the body's primary biological rhythm, thereby achieving consistent system-level physiological modulation.

Circadin is administered through the oral route as a 2 mg prolonged-release tablet for standardized use, following a defined daily administration pattern. The standard regimen mandates taking one 2 mg tablet once daily for a course of up to thirteen weeks as part of a short-term treatment plan. The specific timing instructions require the tablet to be taken after food and consistently 1–2 hours before bedtime.

The physical integrity of the dosage form is essential to its intended function. The prolonged-release tablet must be swallowed whole with water and must not be crushed, chewed, or cut in half under any circumstances. This procedural restriction prevents the rapid release of the active substance, ensuring the sustained delivery required for the intended therapeutic application. If a dose is missed, the patient is not to take a double dose to compensate; the forgotten dose should be taken only if it is before going to sleep, otherwise, the next scheduled dose should be maintained.

Official usage is strictly limited to patients aged 55 years or over. Specific administrative guidance is provided for patients with organ impairment: use is generally not recommended for patients with hepatic impairment due to the potential for markedly elevated systemic melatonin levels. Additionally, caution is advised for patients with renal impairment, as the effect of kidney dysfunction on the medicine's pharmacokinetics remains unstudied in the clinical setting.

Research evidence / Overview of studies for Circadin

Evidence from Trials for Primary Insomnia in Older Adults

The main research for prolonged-release melatonin was evaluated in a series of short-term randomized controlled trials (RCTs). These studies compared the medicine against a placebo (an inactive pill) in Older Adults (aged 55 years or older) diagnosed with primary insomnia (a condition studied in the trials). Research examined the sleep experiences of participants during periods of short-term sleep disturbance.

Researchers primarily monitored patient-reported outcomes describing perceived discomfort related to sleep quality, as well as specific measurements like the time it was studied for how long it took participants to fall asleep (Sleep Latency) and the Total Sleep Time. Findings from these core studies describe patterns where participants taking the prolonged-release formulation reported subjective sleep quality consistent with a modest statistical difference compared to those receiving placebo. Regulatory analyses have noted that the documented change in sleep outcomes was described as small in clinical magnitude.

---

Studies in Specific Patient Groups

Research has explored the use of prolonged-release melatonin in populations outside the main regulatory focus, specifically in children and adolescents (aged 2 to 18 years) with chronic sleep problems associated with neurodevelopmental disabilities (such as Autism Spectrum Disorder). These studies involved randomized, placebo-controlled trials often followed by long-term follow-up periods.

In these pediatric trials, the research examined outcomes reflecting daily functioning or activity level, relying heavily on sleep diaries and parent/carer reports of the children's sleep patterns. Research describes that trials recorded changes in Sleep Latency and Total Sleep Time during the study period. Studies provide information concerning short-term changes in these specific pediatric groups.

---

Duration of Study and Long-Term Follow-up

The main regulatory research primarily focused on research exploring short-term symptom changes, typically assessing outcomes within 3 to 13 weeks. While initial clinical evaluation was studied for short periods, some trials included extension phases that studies explored the effects of continuous use over intermediate durations, such as up to 6 or 12 months. However, long-term effects are not fully established.

---

Areas of Research Uncertainty

Data for certain groups remain insufficient, particularly concerning individuals whose sleep problems are caused by factors other than those related to the age-associated patterns studied. Furthermore, the existing research does not determine whether an individual will respond similarly, and evidence remains limited when considering populations beyond the narrowly defined group of older adults with primary insomnia. Research contributes to understanding but still leaves several gaps.

Key Studies & References

1. Current Insights into the Risks of Using Melatonin as a Treatment for Sleep Disorders in Older Adults (Review of safety and efficacy in older adults)

Common questions about Circadin (FAQ)

---

Q: Can I take Circadin if I am on the contraceptive pill (oestrogens)?

Official information indicates that oestrogens, such as those used in the contraceptive pill or hormone replacement therapy, may affect how Circadin is processed by the body. These substances might increase the level of melatonin in the bloodstream. Regulatory documents note that caution is advised if these medications are used concurrently.

---

Q: Who is eligible to take Circadin?

Circadin is officially indicated for adults aged 55 or over who are experiencing primary insomnia—a condition characterized by poor sleep quality. Official guidance specifies that this medication is used as a short-term treatment to address these sleep disturbances in this specific age group.

---

Q: What should I do with my unused or expired Circadin?

To protect the environment, official regulatory instructions state that Circadin should not be thrown away via wastewater or standard household garbage. Disposal should follow the appropriate pharmaceutical waste protocol, in accordance with national rules for proper medication disposal.

---

Q: Can I drive or operate machinery after taking Circadin?

Regulatory documents indicate that Circadin may moderately affect your ability to drive and use machines. This is because it has the potential to cause drowsiness. Caution is advised if you are involved in any activity where a risk to safety could be associated with feeling sleepy.

---

Q: How does Circadin work in the body?

Circadin works by using a synthetic version of the natural hormone melatonin. According to regulatory information, this substance acts on specific receptors, known as MT1 and MT2 receptors, in the brain to help modulate the body's sleep/wake cycle, also known as the circadian rhythm.

---

Q: How long does it take for Circadin to start working and take effect?

Official product information notes that Circadin is a prolonged-release tablet. This special design means the melatonin is released slowly over a period of several hours to mimic the body’s natural pattern of melatonin secretion during the night. It is recommended that the tablet is taken 1 to 2 hours before bedtime.

---

Q: Can I buy Circadin over-the-counter or do I need a prescription?

Circadin is classified as a prescription-only medicine. Therefore, according to the official product information, it cannot be purchased over-the-counter and requires a valid prescription to be dispensed.

Circadin Storage and Disposal Requirements

Circadin (melatonin prolonged-release tablets) must be stored under specific environmental constraints to preserve its integrity, as documented in official regulatory labeling.

---

Storage Conditions

The medicine must be stored at a temperature not exceeding 25 C. It is mandatory to keep the tablets in the original package to ensure protection from light. Consistent with safety rules, Circadin must be kept out of the sight and reach of children.

---

Disposal Instructions

To discard unused or expired Circadin, the product must not be thrown away via wastewater or ordinary household waste. Disposal must follow the appropriate pharmaceutical waste protocol; consult a pharmacist to ensure the medicine is disposed of in accordance with local requirements.